Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2326 to 2340 of 8933 results

  1. Vilobelimab for treating COVID-19 [TSID11815]

    Awaiting development Reference number: GID-TA11227 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]

    Awaiting development Reference number: GID-TA11305 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]

    Awaiting development Reference number: GID-TA11417 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]

    Awaiting development Reference number: GID-TA11050 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    Awaiting development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development

  7. Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]

    Awaiting development Reference number: GID-TA11806 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

    Awaiting development Reference number: GID-TA11594 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081

    Awaiting development Reference number: GID-TA11705 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]

    Awaiting development Reference number: GID-TA11653 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]

    Awaiting development Reference number: GID-TA11671 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150

    Awaiting development Reference number: GID-TA11783 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development